Videos

Close Video

Overview

Allergy Therapeutics plc (AIM: AGY) has pioneered an ultra-short course allergy treatment (typically acute hayfever), Pollinex Quattro, which in the financial year ending June 2017 year generated revenues in excess of £64m mostly in Europe.

The ability to deliver a disease-modifying outcome as opposed to simply symptomatic relief, with short/ultrashort course treatments significantly differentiates Pollinex Quattro from its competitors.

AGY has established a significant market share in the European market, achieving double-digit compound annual revenue growth over the past 18 years. AGY is seeking to roll out Pollinex Quattro in the US, which has an estimated US$2bn market. To date 15 clinical trials have been completed, including phase I, II & III.

As at 30 June 2018 AGY had a cash balance of £15.5m.

To visit Allergy Therapeutics website, click here

Directors

Manuel Llobet  (CEO)
Joined 2009. Previously CEO of International Operations of the Weinstein family’s group of companies.

Nick Wykeman (FD)
Ex Group Financial Controller of Skyepharma. Held same role at Quest International (part of ICI PLC)

Peter Jensen (NE Chairman)
21yrs with SmithKline Beecham. Previously NED of several listed businesses.

NED’s – Thomas Lander (25 yrs R&D in pharma), Stephen Smith (management accountant), Jeff Barton (VP licensing & acquisitions, Abbott)

Financials

P&L2017
£~000
2016
£~000
Gross Revenue
64,13848,509
Cost of Sales(16,771)(14,070)
Gross Profit47,36734,439
Profit Before Tax/ (Loss)(1,970)(12,064)
Balance Sheet2017
£~000
2016
£~000
Cash & cash equivalents22,12223,406
Total assets57,18356,679
Total liabilities(27,218)(26,355)
Net assets
29.96530,324

Peer Group

ALK (OMX: ALKB)
Grass & ragweed allergy treatment

Stallergenes (EURO: STAGR)
Grass allergy treatment

ALK Abello (CPH: ALK-B)
Research-driven pharma, focused on allergies

DBV Technologies (EPA: DBV)
Biopharmaceutical company focused on food allergies

Shareholders

Directors
Manuel Llobet – 0.55%
Stephen Smith – 0.13%
Peter Jensen – 0.03%
Nick Wykeman – 0.03%

Other
Weinstein A ESQ – 40.49%
Southern Fox Investments Ltd – 21.42%
Odey Asset Management – 7.36%
Invesco AM – 5.74%
Blackrock – 5.11%
GlaxoSmithKlein PLC – 1.70%

Macro Indicators

“…the global vaccine market, in its entirety, has quadrupled in value since 2000 with the World Health Organisation estimating market growth to almost $100bn by 2025.” (Panmure Gordon note, June 2015)

“In the US, it is estimated over 80m people suffer from Allergic Rhinitis (AR), albeit with diagnosis rates which remain low at 31%.” (Panmure Gordon note, June 2015)

Media Coverage

Shares Magazine (May 2018)
“Allergy Therapeutics grass allergy product meets primary objectives” 

Thisismoney.co.uk (May 2018)
“Allergy Therapeutics shares were boosted by positive data from a phase two study for its grass allergy treatment. It paves the way for phase three trials next year. Shares ticked up 9.2 per cent, or, 2.25p to 26.75p.”

The Sunday Times (Sep 2017)
“Children allergic to peanuts could soon be offered a short course of injections to cure them of the condition. AIM-listed Allergy Therapeutics has already tested the vaccine in the laboratory, and is poised to scale up production before applying for approval from regulators. It will then begin human trials.”

Broker Coverage

Panmure Gordon (House Broker, May 2018)
“The Grass MATA MPL (PQ Grass) Phase II does ranging trial (G205) has been a success, with the primary endpoint met, establishing a dose-response relationship and a Phase III dose. Discussions with regulators will be the next immediate step, but this effectively paves the way towards the commencement of the Phase III programme in 2019. Today’s news speaks well to management capabilities in product development, further underlines the effectiveness of the already marketed PQ Grass product and de-risks our investment thesis. “

Submit your details to be kept up to date with announcements regarding Allergy Therapeutics plc

We have a strict data protection policy and will not share your details with external parties.